Abstract
The diagnostic classification and prognostic risk stratification of Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemias (AML) are fundamental for the selection of more effective therapeutic approaches. The resistance of leukemic blasts to standard chemotherapy in the induction phase may result in an inadequate response or failure to achieve complete remission (CR), constituting on…